Viratech Corp. (VIRA: OTC Pink Current) | Kidney Cancer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Viratech Corp. (VIRA: OTC Pink Current) | Kidney Cancer Book #1 Best Seller Status on Amazon.com

  KIDNEY CANCER BOOK ACHIEVES NUMBER 1 BEST SELLER STATUS ON AMAZON.COM

STOCKTON, CALIFORNIA/June 13, 2013 / Newswire/ -- Viratech Corp. (OTC:VIRA) announced today that Cancer.im?s  7 th    book of  235 books slated to be  released on Amazon?s Kindle platform, focusing on Cancer, has achieved number 1 best-seller status for Oncology.

The book, Find & Stop Kidney Cancer by Dr. Kevin Buckman and Cancer Patient Advocate Chris Ryan, has achieved number 1 best-seller status for Oncology. The first book, Find and Stop Breast Cancer, became a best seller earlier this year after only three days. The book Find & Stop Kidney Cancer can be bought here:  http://www.amazon.com/Kidney-Cancer-Find-Stop...d+and+stop

Dr Buckman, states, ?All too often Kidney cancer is found at late stages, since it can be hidden with little or no symptoms.  This book is meant to raise awareness about kidney cancer, and also about cancer in general, and how important that early detection and treatment is.  We dedicated this to a local friend who has kidney cancer spread throughout his body.  He is only 22 years old.?

 The different types of kidney cancer develop in different ways, meaning that the diseases have different outlooks (or prognosis), and need to be staged and treated in different ways. The most common signs and symptoms of kidney cancer are a lump in the abdomen and/or blood in the urine (or hematuria). Other symptoms may include tiredness, loss of appetite, weight loss, a high temperature and heavy sweating, and persistent pain in the abdomen.  However, many of these symptoms can be caused by other conditions, and there may also be no signs or symptoms in a person with kidney cancer, especially in the early stages of the disease.

Cancer is a diverse class of diseases which differ widely in their causes and biology. Any organism can acquire cancer. Nearly all known cancers arise gradually, as errors build up in the cancer cell, and its progeny and cancer cells can be found in our bodies since childhood and increase with age and exposure to carcinogens.

 According to the book, ?Cancer.im (www.cancer.im) is working to find new screening tests for cancer and new modes of therapy. The site, which launched on February 15, 2013, includes a user friendly Mission Adaptive Plan (a MAP) that can be tailored for each user, and 15 modules for dealing with the disease, which are based on the Robert Ryan Cancer Protocol . Based on more than 19 medical studies on quality of life and associated longevity, following the Robert Ryan Cancer Protocol decreases the morbidity of cancer by increasing the quality of life by the use of these 15 steps which allows a cancer patient to be proactive.  There is no charge for this service.? An explanatory video of the power of a Cancer Support Social Network can be seen here: http://www.youtube.com/watch?v=dz1tHRb3wvU

  About Cancer.im

 Through its experience-based search engine and technology, Cancer.im's goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others.  Cancer.im?s mission is to empower every cancer patient with the ability to research their disease and to find, organize, and manage their own cancer support network at no charge to them. The goal of these support networks is to assist the patient in conserving needed energy by reducing the burden associated with their own daily trials and tribulations. Cancer.im will strive to convert this saved energy into a higher level of patient activity and a stronger determination to fight their disease.

 In addition Cancer.im is seeking new cancer researchers who wish to leverage its intellectual property and social network platform for the purpose of creating new distribution and engagement channels.

  About Viratech Corp.

  Viratech Corp. has created the first open source biotech research social network platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology. This has been made possible by leveraging social collaboration in a way that allows new biotech ventures the ability to protect their intellectual property, then simultaneously allowing those same ventures the ability to promote and crowdsource their development.

Contact: Kevin Buckman MD

Viratech, Corp.

http://viratech.org

Email Contact: info@viratech.org

209-477-3030

 

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading